Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quercus virginiana pollen is a non-standardized allergenic extract derived from the pollen of the Virginia Live Oak tree (Quercus virginiana). [5] Marketed under the brand name 'Virginia Live Oak Pollen' and manufactured by Greer Laboratories, Inc., it is an FDA-approved biologic product used for both diagnosis and treatment of individuals with immediate hypersensitivity allergies to this specific pollen. The diagnostic application involves skin testing to confirm sensitivity. The therapeutic use consists of allergen immunotherapy, where the extract is administered via intradermal, percutaneous, or subcutaneous injection. This process aims to modulate the patient's immune system to build tolerance to the allergen, involving mechanisms such as the induction of cell-mediated immunity and an increase in allergen-specific IgG antibodies, which can block the allergic reaction. [1] The product was first approved by the FDA in 1941.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quercus virginiana pollen.